News >

Adjuvant Treatment Evolving for HER2+ Breast Cancer

Angelica Welch
Published: Monday, Nov 27, 2017

Sara Tolaney, MD, MPH
Sara Tolaney, MD, MPH
With the FDA approval of neratinib (Nerlynx) earlier this year, and the recent priority review designation of pertuzumab (Perjeta), treatment options for patients with HER2-positive breast cancer continue to advance.

, Tolaney, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discussed the state of adjuvant treatment for patients with HER2-positive breast cancer.

OncLive: What does the adjuvant landscape look like in HER2-positive disease?

Tolaney: [Adjuvant treatment for HER2-positive breast cancer] has evolved over the past few years. We have seen outcomes from 6 pivotal studies that have shown that adding trastuzumab to chemotherapy dramatically improves disease-free and overall survival. Despite this, 15% of patients with HER2-positive cancer still recur. There has been a need to try to do more to improve outcomes. There are 2 particular drugs that I focused on; one was pertuzumab and the other was neratinib. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication